Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- View the Talks
-
1. Mononuclear phagocytes - origins, fates and functions
- Prof. Steffen Jung
-
2. Transcription factors in macrophage differentiation
- Dr. Michael Sieweke
-
3. Fetal macrophages
- Prof. Paul Martin
-
4. The alveolar macrophage
- Dr. Ronald G. Crystal
-
5. Airway macrophages in health and disease
- Prof. Tracy Hussell
-
6. Intestinal macrophages - heterogeneity, origins and functions
- Prof. Allan Mowat
-
7. Osteoclasts: what do they do and how do they do it?
- Prof. Steven L. Teitelbaum
-
8. The biology of Fc receptors and complement receptors
- Prof. Steven Greenberg
-
10. Tumour-associated macrophages
- Prof. Michele De Palma
- Dr. Mario Squadrito
-
11. The recognition of pathogens by C-type lectins
- Prof. Gordon D. Brown
-
12. Macrophage phagocytosis
- Prof. Joel Swanson
-
13. Macrophage CD36 and atherosclerosis
- Dr. Maria Febbraio
-
14. Toll-Like receptor signaling and the innate immune response
- Dr. Kate Fitzgerald
-
15. Innate immune receptors as mediators of systemic inflammation and pathogenesis of malaria
- Prof. Ricardo Gazzinelli
-
17. Triggering receptors expressed on myeloid cells (TREM)
- Dr. Daniel W. McVicar
-
18. Influence of eicosanoid lipid mediators on macrophage innate immune functions
- Prof. Marc Peters-Golden
-
19. Macrophage paired receptor interactions
- Prof. Neil Barclay
-
20. Macrophage heterogeneity in atherosclerosis regression
- Prof. Edward Fisher
-
21. Gaucher disease: from lysosomal storage to immunopathology
- Prof. Johannes M.F.G. Aerts
-
22. Macrophage in asthma
- Prof. Douglas Robinson
-
23. The macrophage mannose receptor
- Dr. Luisa Martinez-Pomares
-
24. Myeloid-derived suppressor cells in cancer
- Prof. Dmitry Gabrilovich
-
25. EGF-TM7 receptors
- Dr. Jörg Hamann
- Dr. Hsi-Hsien Lin
-
26. Macrophages in helminth infection
- Prof. Judith Allen
- Archived Lectures *These may not cover the latest advances in the field
-
27. Immunosuppressive mechanisms in myeloid cells
- Prof. Dmitry Gabrilovich
Printable Handouts
Navigable Slide Index
- Introduction
- Tumor microenvironment is a complex system
- Myeloid cells in cancer exist in two functional states
- Myeloid cells are associated with bad clinical outcome in cancer
- How myeloid cells developed in pathological conditions
- The transcriptional trajectory of neutrophils development
- Tumor associated macrophages and MDSC regulate tumor progression
- Regulation of MDSC development
- Two-signal concept of MDSC development
- Phenotype of MDSC in comparison to neutrophils and monocytes
- Surface markers and genes associated with MDSC
- Immunosuppressive activity of MDSC
- Gene expression profile of macrophages
- Suppressive activity of macrophages (humans)
- Suppressive activity of macrophages (mice)
- Adoptive transfer
- S100A9 expression in macrophages
- Effect of S100A9 on suppressive activity
- Melanoma patients treated with PD1 antibody
- Heterogeneity of neutrophils in cancer
- Three populations of neutrophils in cancer
- Different dynamic of PMN-MDSC accumulation
- Activated tumor PMN-MDSC are highly suppressive
- Trajectory analysis
- Clinical relevance of tumor PMN-MDSC signature
- Populations of human neutrophils
- Balance of power in MDSC regulation
- IFNAR1 is downregulated in MDSCs
- Absence of IFNAR1 is not enough to convert neutrophils to PMN-MDSC
- IFN1 signaling is involved in negative regulation of MDSC
- MDSC suppressive activity is abrogated in SA mice
- Ferroptosis
- Tumor neutrophils demonstrated enrichment for ferroptosis related genes
- Enrichment for ferroptosis signature in tumor PMN
- Accumulation of oxidized PE in tumor PMN
- Ferroptosis susceptibility
- Ferroptosis induction converted PMN to PMN-MDSC
- Suppressive activity of tumor but not spleen PMN-MDSC is controlled by ferroptosis
- Inhibition of ferroptosis resulted in decreased tumor progression
- Pharmacological induction of ferroptosis promoted tumor growth
- Ferroptosis signature in cancer patients
- Myeloid cells at the center of therapeutic effort
- Approaches to target myeloid cells in cancer
- How can we use myeloid cell targeting
- Multiple approaches to target myeloid cells in cancer
- Thank you
Topics Covered
- Myeloid cells in cancer
- Tumor associated macrophages and MDSC regulate tumor progression
- Immunosuppressive activity of MDSC
- Effect of S100A9 on suppressive activity
- IFNAR1 is downregulated in MDSCs
- Ferroptosis
- Approaches to target myeloid cells in cancer
Links
Series:
- The Immune System - Key Concepts and Questions
- Immunotherapy of Cancer
- Macrophage Heterogeneity and Function
Categories:
Therapeutic Areas:
Talk Citation
Gabrilovich, D. (2024, February 29). Myeloid-derived suppressor cells in cancer [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/RXZP5320.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Gabrilovich is an employee and stakeholder of AstraZeneca, however no products of AstraZeneca or any other companies are discussed.
A selection of talks on Cell Biology
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Dmitry Gabrilovich
and for many years, I was
an academic researcher,
professor at different
institutions
working on myeloid cell biology.
For the last three
and a half years,
I am the Executive Director and
Chief Scientist at AstraZeneca,
where I'm continuing working on
basic and translational aspect
of myeloid cell biology,
specifically myeloid-derived
suppressor cells.
I will be discussing
with you today
the basic biology of
myeloid cells in cancer,
especially myeloid-derived
suppressor cells,
and really illustrate
their biology
with several examples
of our recent studies.
0:38
Tumor microenvironment is
full of myeloid cells.
They represent one
of the major part
of this microenvironment.
Myeloid cells in cancer
are largely represented by
tumor associated macrophages
and neutrophils and monocytes,
and specifically their
pathological state of activation,
myeloid-derived suppressor cells
from which I will be
discussing a little bit later.
There's also dendritic
cells present in tumors.
The main message, what we
learned in the last
several decades
is that practically all tumors
are infiltrated
with myeloid cells.
There is no such thing as
a cold tumor in respect
of myeloid cells.
They play a major role
in the regulation of
immune responses in
cancer and promoting
tumor progression through
non-immunological means,
meaning affecting angiogenesis,
extracellular matrix,
and many other things.
As I said, myeloid
cells represent
very diverse group of cells with
multiple different
functionalities
and they produce multiple
different factors.
From the long time,
the question was:
what defines the functions
of these myeloid
cells in cancer?
That is myeloid cells really
exist to regulate tumor
because in evolution,
these cells
are one of our major
protectors from pathogens.
So why these things
changed in cancer?
That's what we try
to figure out for
the last 20 years
and we come up with
a clear and
functional hypothesis
which has been confirmed
in many different studies,
but still under debate,
which I will discuss
with you right now.